CRSP

CRISPR Therapeutics AG

83.89 USD
+0.14 (+0.17%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

CRISPR Therapeutics AG stock is up 29.56% since 30 days ago. The next earnings date is May 6, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 7 March’s closed higher than February. In the last 10 Unusual Options Trades, there were 7 CALLs, 3 PUTs. 29% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
29 Feb 18:36 19 Apr, 2024 75.00 CALL 20 2015
29 Feb 19:09 16 Jan, 2026 85.00 CALL 15 592
01 Mar 14:51 19 Apr, 2024 100.00 CALL 93 691
01 Mar 15:03 01 Mar, 2024 62.00 CALL 16 35
01 Mar 15:06 15 Mar, 2024 87.00 CALL 100 93
01 Mar 15:21 01 Mar, 2024 61.00 CALL 17 28
01 Mar 15:33 19 Apr, 2024 90.00 PUT 50 29
01 Mar 16:02 19 Apr, 2024 90.00 PUT 46 29
01 Mar 17:01 19 Apr, 2024 85.00 CALL 40 2359
01 Mar 20:11 19 Apr, 2024 115.00 PUT 10 10

About CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases. The company's lead product candidate is CTX001, an ex-viggered therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies.

  • Morgan Stanley
    Mon Feb 26, 10:45
    sell
    confirm
  • RBC Capital
    Thu Feb 22, 12:38
    hold
    confirm
  • Wells Fargo
    Thu Feb 22, 11:41
    hold
    confirm
  • Barclays
    Thu Feb 22, 10:41
    hold
    confirm
  • Chardan Capital
    Thu Feb 22, 05:42
    buy
    confirm
  • Needham
    Wed Feb 21, 11:39
    buy
    confirm
  • Wolfe Research
    Thu Feb 15, 06:56
    hold
    initial